發(fā)布時間：2018-03-06 10:53

  本文選題：血管生成抑制劑　切入點(diǎn)：復(fù)發(fā)性卵巢癌　出處：《中國實(shí)用婦科與產(chǎn)科雜志》2017年03期 　論文類型：期刊論文

【摘要】：目的探討血管生成抑制劑聯(lián)合化療治療復(fù)發(fā)性卵巢癌的療效與安全性。方法檢索Pub Med、Embase、Cochrane Library、中國生物醫(yī)學(xué)文獻(xiàn)數(shù)據(jù)庫、中國知網(wǎng)、維普與萬方數(shù)據(jù)庫,收集和評價國內(nèi)外從建庫至2016年1月血管生成抑制劑聯(lián)合化療與常規(guī)化療相比較治療復(fù)發(fā)性卵巢癌的療效與安全性的隨機(jī)對照試驗(RCT)。由2名研究者獨(dú)立篩選提取文獻(xiàn)資料、評價偏倚風(fēng)險后,采用Rev Man5.3軟件進(jìn)行Meta分析。結(jié)果共納入6個RCT,2028例復(fù)發(fā)性卵巢癌患者。結(jié)果顯示:(1)血管生成抑制劑聯(lián)合化療組較常規(guī)化療組(對照組)可延長總生存期(OS)[HR=0.87,95%CI(0.76,0.99)]和無進(jìn)展生存期(PFS)[HR=0.56,95%CI(0.47,0.67)],差異均有統(tǒng)計學(xué)意義(P0.05)。(2)藥物安全性結(jié)果顯示:≥3級總不良反應(yīng)發(fā)生率血管生成抑制劑聯(lián)合化療組與對照組間差異無統(tǒng)計學(xué)意義(P0.05),常見不良反應(yīng)中抗血管內(nèi)皮生長因子(anti-VEGF)抑制劑聯(lián)合化療組≥3級高血壓、蛋白尿發(fā)生率較高;抗血管內(nèi)皮生長因子受體(anti-VEGFR)抑制劑聯(lián)合化療組≥3級蛋白尿及≤2級腹瀉、嘔吐等不良反應(yīng)發(fā)生率較高;抗促血管生成素(anti-ANG)抑制劑聯(lián)合化療組≤2級外周水腫發(fā)生率較高,以上差異均有統(tǒng)計學(xué)意義(P0.05)。結(jié)論血管生成抑制劑聯(lián)合化療可提高復(fù)發(fā)性卵巢癌患者OS及PFS,總不良反應(yīng)發(fā)生率與常規(guī)化療組相當(dāng)。不同作用機(jī)制的血管生成抑制劑發(fā)生不良反應(yīng)類型及嚴(yán)重程度具有一定差異。
[Abstract]:Objective to investigate the efficacy and safety of angiogenesis inhibitor combined with chemotherapy in the treatment of recurrent ovarian cancer. Methods Pub Medbase Cochrane Library, Chinese Biomedical Literature Database, China knowledge Network, Weip and Wanfang databases were searched. To collect and evaluate the efficacy and safety of angiogenesis inhibitors combined with chemotherapy and conventional chemotherapy in the treatment of recurrent ovarian cancer from the establishment of the bank to January 2016, a randomized controlled trial was conducted to collect and evaluate the efficacy and safety of chemotherapy in the treatment of recurrent ovarian cancer. After evaluating the risk of bias, Meta analysis was carried out with Rev Man5.3 software. Results A total of 2 028 patients with recurrent ovarian cancer were included in this study. The results showed that the total survival time of the angiogenesis inhibitor combined chemotherapy group was significantly longer than that of the conventional chemotherapy group (control group). Survival time (PFS) [HRN 0.5695 CIQ 0.470.67], the difference was statistically significant (P 0.05. 0. 0. 2) the results showed that there was no significant difference between the angiogenesis inhibitor combined with chemotherapy group and the control group in the incidence of total adverse drug reactions (鈮，

本文編號：1574545